The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer

Journal of Surgical Oncology

Volumn 110, Issue 4, 2014, Pages 451-457

  Lin, Chun Chi ^a,b   Lin, Jen Kou ^a,b   Lin, Tzu Chen ^a,b   Chen, Wei Shone ^a,b   Yang, Shung Haur ^a,b   Wang, Huann Sheng ^a,b   Lan, Yuan Tzu ^a,b   Jiang, Jeng Kai ^a,b   Yang, Muh Hwa ^a,b   Chang, Shih Ching ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

BRAF mutation; colon cancer; KRAS mutation; microsatellite instability; prognosis

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CODON; COLON CANCER; FEMALE; GENOTYPE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIORITY JOURNAL;

BRAF MUTATION; COLON CANCER; KRAS MUTATION; MICROSATELLITE INSTABILITY; PROGNOSIS;

AGED; CODON; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84905739060     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23675     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Zlobec I, Lugli A:, Prognostic and predictive factors in colorectal cancer. J Clin Pathol 2008; 61: 561-569.
3. Gunderson LL, Jessup JM, Sargent DJ, et al.: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-271.
4. Ross JS, Torres-Mora J, Wagle N, et al.: Biomarker-based prediction of response to therapy for colorectal cancer: Current perspective. Am J Clin Pathol 2010; 134: 478-490.
5. Vilar E, Gruber SB:, Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010; 7: 153-162.
6. Lin CC, Lai YL, Lin TC, et al.: Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis 2012; 27: 277-286.
7. Alexander J, Watanabe T, Wu TT, et al.: Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527-535.
8. Popat S, Hubner R, Houlston RS:, Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618.
9. Schubbert S, Shannon K, Bollag G:, Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
10. Phipps AI, Buchanan DD, Makar KW, et al.: KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers. Br J Cancer 2013; 108: 1757-1764.
11. Normanno N, Tejpar S, Morgillo F, et al.: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527.
12. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90: 675-684.
13. Imamura Y, Morikawa T, Liao X, et al.: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18: 4753-4763.
14. Conlin A, Smith G, Carey FA, et al.: The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005; 54: 1283-1286.
15. Lin AY, Buckley NS, Lu AT, et al.: Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: A systematic review and meta-analysis. Clin Colorectal Cancer 2011; 10: 63-69.
16. Bokemeyer C, Van Cutsem E, Rougier P, et al.: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475.
17. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001; 85: 692-696.
18. Richman SD, Seymour MT, Chambers P, et al.: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
19. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
20. Ren J, Li G, Ge J, et al.: Is K-ras gene mutation a prognostic factor for colorectal cancer: A systematic review and meta-analysis. Dis Colon Rectum 2012; 55: 913-923.
21. Peyssonnaux C, Eychene A:, The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell 2001; 93: 53-62.
22. French AJ, Sargent DJ, Burgart LJ, et al.: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408-3415.
23. Ogino S, Shima K, Meyerhardt JA, et al.: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012; 18: 890-900.
24. Samowitz WS, Sweeney C, Herrick J, et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069.
25. Zlobec I, Kovac M, Erzberger P, et al.: Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer 2010; 127: 2569-2575.
26. Ogino S, Nosho K, Kirkner GJ, et al.: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96.
27. Yokota T, Ura T, Shibata N, et al.: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-862.
28. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al.: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.
29. Di Nicolantonio F, Martini M, Molinari F, et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
30. Tol J, Koopman M, Cats A, et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
31. Tol J, Nagtegaal ID, Punt CJ:, BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.
32. Lao VV, Grady WM:, Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
33. Weisenberger DJ, Siegmund KD, Campan M, et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
34. Domingo E, Espin E, Armengol M, et al.: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138-142.
35. Lee S, Cho NY, Choi M, et al.: Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58: 104-113.
36. Edge S, Byrd DR, Compton CC, et al.: AJCC cancer staging manual. Springer; 2010.
37. Compton CC, Fielding LP, Burgart LJ, et al.: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
38. Chang SC, Lin JK, Yang SH, et al.: Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 2006; 118: 1721-1727.
39. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
40. Forbes SA, Bindal N, Bamford S, et al.: COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
41. Lin JK, Chang SC, Wang HS, et al.: Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. J Surg Oncol 2006; 94: 234-241.
42. Teng HW, Huang YC, Lin JK, et al.: BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2012; 106: 123-129.
43. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
44. Westra JL, Schaapveld M, Hollema H, et al.: Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005; 23: 5635-5643.
45. Price TJ, Hardingham JE, Lee CK, et al.: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 2011; 29: 2675-2682.
46. Kim ST, Lee J, Park SH, et al.: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66: 659-667.
47. Urosevic N, Krtolica K, Skaro-Milic A, et al.: Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 1993; 54: 249-254.
48. Nash GM, Gimbel M, Cohen AM, et al.: KRAS mutation and microsatellite instability: Two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 2010; 17: 416-424.
49. Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al.: Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996; 111: 307-317.
50. Oliveira C, Westra JL, Arango D, et al.: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-2311.
51. Finkelstein SD, Sayegh R, Christensen S, et al.: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71: 3827-3838.
52. Bazan V, Migliavacca M, Zanna I, et al.: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438-1446.
53. Samowitz WS, Curtin K, Schaffer D, et al.: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-1197.
54. Winder T, Mundlein A, Rhomberg S, et al.: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 2009; 21: 1283-1287.
55. Cushman-Vokoun AM, Stover DG, Zhao Z, et al.: Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Clin Colorectal Cancer 2013; 12: 168-178.
56. Edkins S, O'Meara S, Parker A, et al.: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5: 928-932.
57. Buhrman G, Wink G, Mattos C:, Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 2007; 15: 1618-1629.
58. Feig LA, Cooper GM:, Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol 1988; 8: 2472-2478.
59. Loupakis F, Ruzzo A, Cremolini C, et al.: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.